These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36168818)

  • 21. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C.
    Katzmann JL; Sorio-Vilela F; Dornstauder E; Fraas U; Smieszek T; Zappacosta S; Laufs U
    Clin Res Cardiol; 2022 Mar; 111(3):243-252. PubMed ID: 32949286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
    Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
    Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project.
    Laufs U; Catapano AL; De Caterina R; Schiele F; Sionis A; Zaman A; Jukema JW
    Vascul Pharmacol; 2023 Feb; 148():107141. PubMed ID: 36626974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
    Lancet; 2021 Nov; 398(10312):1713-1725. PubMed ID: 34506743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty.
    Wolf S; Spirk D; Forgo G; Sebastian T; Voci D; Kucher N; Barco S
    Vasa; 2022 Nov; 51(6):357-364. PubMed ID: 36052607
    [No Abstract]   [Full Text] [Related]  

  • 31. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy.
    Sciattella P; Maggioni AP; Arcangeli E; Sidelnikov E; Kahangire DA; Mennini FS
    Adv Ther; 2022 Jan; 39(1):314-327. PubMed ID: 34718949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement.
    McCaughey C; Ranganathan D; Kerins M; Murphy G; Murphy R
    Ir J Med Sci; 2022 Dec; 191(6):2569-2577. PubMed ID: 35031936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population.
    Raal F; Schamroth C; Patel J; Becker P
    Cardiovasc J Afr; 2007; 18(5):325-9. PubMed ID: 17985033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction.
    Qureshi N; Antoniou S; Cornel JH; Schiele F; Perrone-Filardi P; Brachmann J; Sidelnikov E; Villa G; Ferguson S; Rowlands C; González-Juanatey JR
    Adv Ther; 2023 Jan; 40(1):233-251. PubMed ID: 36289145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.
    Ara R; Tumur I; Pandor A; Duenas A; Williams R; Wilkinson A; Paisley S; Chilcott J
    Health Technol Assess; 2008 May; 12(21):iii, xi-xiii, 1-212. PubMed ID: 18485273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.